Joshua P Plotnik - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Joshua P Plotnik

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Molecular Cancer Therapeutics|March 20, 2024

Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell LymphomaJoshua P Plotnik, Adam E Richardson, Haopeng Yang, et al.

Molecular Cancer Therapeutics|July 13, 2021

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Tianyu Cai, Xiaoyu Lin, et al.

Nature|January 24, 2020

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J Faivre, Keith F McDaniel, Daniel H Albert, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Molecular Cancer Therapeutics|March 20, 2024

Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell LymphomaJoshua P Plotnik, Adam E Richardson, Haopeng Yang, et al.

Molecular Cancer Therapeutics|July 13, 2021

Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid LeukemiaLu Zhang, Tianyu Cai, Xiaoyu Lin, et al.

Nature|January 24, 2020

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J Faivre, Keith F McDaniel, Daniel H Albert, et al.

Pageof 2